Cargando…

Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting

This review summarizes the significant advancements in prophylaxis against graft-versus-host disease (GvHD) presented at the 2022 ASH Annual Meeting. The use of innovative agents and regimens, along with the conventional prophylactic approach of combining post-transplant cyclophosphamide and anti-th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yiyin, Xu, Yang, Wu, Depei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326945/ https://www.ncbi.nlm.nih.gov/pubmed/37420283 http://dx.doi.org/10.1186/s40164-023-00425-y

Ejemplares similares

Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
por: Cao, Yang, et al.
Publicado: (2023)

Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting
por: Tan, Jiaxiong, et al.
Publicado: (2023)

Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH Annual Meeting
por: Xu, Jieyu, et al.
Publicado: (2023)

CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting
por: Huang, Qiusha, et al.
Publicado: (2023)

Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting
por: DiNardo, Katherine W., et al.
Publicado: (2023)

Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
por: Wang, Chaoyu, et al.
Publicado: (2023)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
por: Gong, Xubo, et al.
Publicado: (2023)

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
por: Xia, Jieyun, et al.
Publicado: (2023)

Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting
por: Yin, Xuejiao, et al.
Publicado: (2023)

Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference
por: Wang, Andrew, et al.
Publicado: (2023)

Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting
por: Lin, Zhijuan, et al.
Publicado: (2023)

Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
por: Hou, Jiangxue, et al.
Publicado: (2023)

CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
por: Liu, Xinyuan, et al.
Publicado: (2023)

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
por: Wu, James F., et al.
Publicado: (2023)

Recent advances in myelodysplasia: update from 2011 ASH annual meeting
por: Liu, Delong
Publicado: (2012)

CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
por: Huang, Ruihao, et al.
Publicado: (2023)

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
por: Zhao, Juanjuan, et al.
Publicado: (2023)

Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting
por: Guo, Ruiting, et al.
Publicado: (2022)

End-of-2022 stocktake update
por: Weightman, Michael, et al.
Publicado: (2023)

2022 ASCO Annual Meeting: Takeaways for the Advanced Practitioner
por: Faiman, Beth
Publicado: (2022)

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
por: Hou, Jing-Zhou, et al.
Publicado: (2021)

Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
por: Wang, Ji-nuo, et al.
Publicado: (2022)

Virginia Dental Society—Annual Meeting
por: Burton, W. Leigh
Publicado: (1867)

ASENT 2022 Annual Meeting
Publicado: (2022)

A Rare Presentation of Acute on Chronic Graft Versus Host Disease
por: Khurana, Surbhi, et al.
Publicado: (2022)

Cutaneous Chronic Graft versus Host Disease Mimicking Verruca Vulgaris
por: Jagadeesan, Soumya, et al.
Publicado: (2023)

Melanoma: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner
Publicado: (2022)

Incorporating Scientific Advances and Improving Access to Care: Meeting Abstracts From the 2021 ASH Annual Meeting and Exposition
por: Kurtin, Sandra E.
Publicado: (2022)

2022 ASCB Annual Meeting abstracts
Publicado: (2023)

SCTS Annual Meeting 2022 Abstracts
Publicado: (2023)

Gynecologic Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner
Publicado: (2022)

Hematologic Malignancies: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner
Publicado: (2022)

Breast Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner
Publicado: (2022)

Genitourinary Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner
Publicado: (2022)

Thoracic Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner
Publicado: (2022)

Gastrointestinal Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner
Publicado: (2022)

Multiple spider angiomas in a patient with chronic hepatic graft-versus-host disease
por: Gu, Ying, et al.
Publicado: (2020)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
por: Yu, Jiazheng, et al.
Publicado: (2023)

Transfusion Associated Graft Versus Host Disease
por: Naveen, Kikkeri Narayanshetty, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pffa1u4rcl854rjdi6pfdqst86